Gene expression data from MCF7 breast adenocarcinoma cells treated with prolactin and/or bufexamac. Homo sapiens

The hormone prolactin is implicated in the pathogenesis of breast cancer, and a subset of prolactin-induced gene expression is mediated by HDAC6 activity. The NSAID, bufexamac, is a fairly specific inhibitor of HDAC6 and HDAC10. We used bufexamac in combination with prolactin treatment in MCF7 cells to determine differential expression under these conditions. Overall design: MCF7 cells were serum starved for 24 hours prior to treatment with bufexamac and/or prolactin, and subsequent RNA extraction.